<DOC>
	<DOCNO>NCT02071602</DOCNO>
	<brief_summary>The primary endpoint ass safety tolerability Cenderitide ( CD-NP ) incidence symptomatic hypotension one key safety variable .</brief_summary>
	<brief_title>CD-NP ( Cenderitide ) Therapy Preservation Left Ventricular Function</brief_title>
	<detailed_description>This `` proof concept '' , randomize , double-blind , placebo control study . The study population include 60 patient admit first time ST elevation anterior STEMI diagnose follow criterion : ) Significant chest discomfort /or shortness breath ; b ) ST segment elevation ( 1.5 mV total ) two adjacent anterior precordial lead ; c ) Successful reperfusion therapy ( &gt; TIMI grade 2 flow ) either thrombolytic PTCA within 24 hour onset symptom document coronary angiography ; ) No previous history anterior AMI previous ECG suggest old anterior AMI . Patients randomize one two dos CD-NP ( 5 ng/kg/min 10 ng/kg/min ) placebo continuous infusion 72 hour 1:1:1 manner . All patient receive standard medical therapy determine appropriate physician accordance ACC/AHA guideline</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Significant chest discomfort /or shortness breath ST segment elevation ( 1.5 mV total ) two adjacent anterior precordial lead Successful reperfusion therapy ( &gt; TIMI grade 2 flow ) either thrombolytics mechanical form revascularization , include stent , PTCA , thrombectomy , etc . within 24 hour onset symptom document coronary angiography No previously know history AMI ( prior current cardiac event ) previous ECG ( prior current cardiac event ) suggest old AMI ( Q wave present ECG exclusion ) .. ( Assessed time enrollment unless otherwise state ) Cardiogenic shock , acute heart failure hypotension ( Systolic BP &lt; 90 mmHg ) Previous know decrease EF &lt; 40 % Atrial Fibrillation Persistent sign symptom Post MI ischemia Requirement pressor maintenance blood pressure . Intraaortic blood pump use Significant ( moderatesevere ) valvular stenosis , hypertrophic , restrictive obstructive cardiomyopathy , constrictive pericarditis , primary pulmonary hypertension . Severe congenital heart disease Sustained ventricular tachycardia ventricular fibrillation Second third degree heart block without permanent cardiac pacemaker Stroke within 3 month evidence significantly compromise CNS perfusion Total bilirubin &gt; 2.5 mg/dL liver enzymes &gt; 2.5 time upper limit normal available clinically measure within last 7 day Patients calculate GFR &lt; 30 ml MDRD equation acute kidney injury define increase plasma creatinine 0.5 mg/dL plasma creatinine measure within last 7 day Serum sodium &lt; 125 mEq/dL &gt; 160 mEq/dL available clinically measure within last 7 day Serum potassium &lt; 3.0 mEq/dL &gt; 5.8 mEq/dL available clinically measure within last 7 day Hemoglobin &lt; 8.5 gm/dl available clinically measure within last 7 day Other acute chronic medical condition laboratory abnormality may increase risk associate study participation may interfere interpretation data Received investigational drug within 1 month prior dose Female subject pregnant breastfeeding In opinion investigator , unlikely comply study protocol unsuitable reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Heart attack</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>STEMI</keyword>
</DOC>